Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Biofrontera AG
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Asia Deal Watch: Antibody-Drug Conjugates Reign With Alliances Involving Celltrion, Miracogen & WuXi Biologics
Celltrion and iProgen will co-develop ADC candidates, Miracogen and Synaffix sign a technology license after a successful research collaboration, and WuXi will provide clinical trial material to NBE Therapeutics.
Two Phase III studies of KX2-391 to treat actinic keratosis of the face and scalp met their primary endpoint of 100% clearance. The treatment could prove more convenient than marketed therapies.
Public Company Edition: With returns for newly public biopharma companies rising, seven more jumped in line to go public in the US between the beginning of February and early March, while two drug developers launched IPOs in the EU. Meanwhile, already public companies keep raising gobs of cash.
- Other Names / Subsidiaries
- Biofrontera Bioscience GmbH
- Biofrontera Development GmbH
- Biofrontera Pharma GmbH
- Cutanea Life Sciences, Inc.